Vaxart (NASDAQ:VXRT) released its quarterly earnings results on Tuesday. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04, Zacks reports. The business had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.44 million. Vaxart had a negative return on equity of 131.05% and a negative net margin of 244.38%.
NASDAQ VXRT traded down $0.01 on Wednesday, reaching $0.32. 2,458 shares of the company’s stock traded hands, compared to its average volume of 550,066. The firm has a market cap of $5.45 million, a price-to-earnings ratio of -0.12 and a beta of 0.55. The stock has a 50 day moving average price of $0.35 and a 200-day moving average price of $0.60. Vaxart has a fifty-two week low of $0.25 and a fifty-two week high of $5.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.29 and a current ratio of 2.29.
Several equities analysts recently commented on VXRT shares. HC Wainwright set a $2.00 target price on Vaxart and gave the stock a “buy” rating in a research report on Wednesday, August 21st. Brookline Capital Management began coverage on Vaxart in a research report on Thursday, August 15th. They set a “buy” rating and a $6.00 price objective for the company. ValuEngine lowered Vaxart from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Zacks Investment Research upgraded Vaxart from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a research report on Sunday, November 3rd.
Vaxart Company Profile
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.
Featured Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.